- Home
- PAXS vs BBNX Comparison
PAXS vs BBNX Comparison
Compare PAXS & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAXS
- BBNX
- Stock Information
- Founded
- PAXS 2021
- BBNX 2015
- Country
- PAXS United States
- BBNX United States
- Employees
- PAXS N/A
- BBNX N/A
- Industry
- PAXS Investment Managers
- BBNX Medical/Dental Instruments
- Sector
- PAXS Finance
- BBNX Health Care
- Exchange
- PAXS Nasdaq
- BBNX Nasdaq
- Market Cap
- PAXS 723.1M
- BBNX 740.7M
- IPO Year
- PAXS N/A
- BBNX 2025
- Fundamental
- Price
- PAXS $16.26
- BBNX $26.41
- Analyst Decision
- PAXS
- BBNX Strong Buy
- Analyst Count
- PAXS 0
- BBNX 10
- Target Price
- PAXS N/A
- BBNX $24.40
- AVG Volume (30 Days)
- PAXS 195.0K
- BBNX 690.5K
- Earning Date
- PAXS 01-01-0001
- BBNX 11-06-2025
- Dividend Yield
- PAXS 11.72%
- BBNX N/A
- EPS Growth
- PAXS N/A
- BBNX N/A
- EPS
- PAXS N/A
- BBNX N/A
- Revenue
- PAXS N/A
- BBNX $69,830,000.00
- Revenue This Year
- PAXS N/A
- BBNX $42.80
- Revenue Next Year
- PAXS N/A
- BBNX $34.58
- P/E Ratio
- PAXS N/A
- BBNX N/A
- Revenue Growth
- PAXS N/A
- BBNX 38911.17
- 52 Week Low
- PAXS $12.57
- BBNX $8.89
- 52 Week High
- PAXS $15.93
- BBNX $26.66
- Technical
- Relative Strength Index (RSI)
- PAXS 70.54
- BBNX 85.28
- Support Level
- PAXS $15.46
- BBNX $18.12
- Resistance Level
- PAXS $16.46
- BBNX $19.32
- Average True Range (ATR)
- PAXS 0.10
- BBNX 1.35
- MACD
- PAXS 0.02
- BBNX 0.75
- Stochastic Oscillator
- PAXS 72.16
- BBNX 97.43
About PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.
About BBNX Beta Bionics Inc. Common Stock
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.